Apogee Therapeutics (APGE) Price & Analysis

Compare

302 Followers

APGE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$26.20 - $63.50

Previous CloseN/A

Volume109.80K

Average Volume (3M)522.38K

Market Cap

$2.26B

Enterprise Value$2.04B

Total Cash (Recent Filing)$505.42M

Total Debt (Recent Filing)$10.85M

Price to Earnings (P/E)―

Beta1.69

Next Earnings

Nov 18, 2025

EPS Estimate

-1.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.13

Shares Outstanding46,109,768

10 Day Avg. Volume671,763

30 Day Avg. Volume522,384

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.90

Enterprise Value/Revenue15.72K

Enterprise Value/Gross Profit-3.46K

Enterprise Value/Ebitda-7.55

Forecast

1Y Price Target

$93.67

Price Target Upside143.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Efficacy And Market PotentialAPG777 demonstrated best-in-class efficacy and clean safety in atopic dermatitis.

Financial StabilityAPGE has sufficient cash to fund operations into 1Q28, supporting its financial stability and ongoing development plans.

Market PositionAPG777 is in the pole position to emerge as the preferred treatment option in atopic dermatitis.

Bears Say

Competitive LandscapeA head-to-head trial of APG279 vs. Dupixent is underway, aiming to validate APG279’s potential to deliver a broader immunosuppressive effect.

Apogee Therapeutics News

Apogee Therapeutics initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Apogee Therapeutics (APGE) with an Outperform rating and $60 price target The firm...

1d ago

APGE

Wall Street Sees Massive Growth Potential in These 3 Russell 2000 Stocks

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have...

23d ago

APGE

BEAM

3 Best Stocks to Buy Now, 8/28/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

28d ago

NXE

APGE

Apogee Therapeutics price target raised to $87 from $78 at BofA

BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics (APGE) to $87 from $78 and...

29d ago

APGE

Promising Prospects for Apogee Therapeutics: Buy Rating Backed by Strong Trial Results and Financial Health

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Apogee Therapeutics. The associated price target remains...

2M ago

APGE

Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges

Apogee Therapeutics, Inc. (APGE) has disclosed a new risk, in the Supply Chain category. Apogee Therapeutics, Inc.’s reliance...

2M ago

APGE

Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position

Apogee Therapeutics, Inc. ( ($APGE) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

APGE

Apogee Therapeutics reports Q2 net loss ($66.1M) vs ($33.816M) last year

“We are proud of the strong execution across our pipeline in the first half of 2025, highlighted by...

2M ago

APGE

Apogee Therapeutics expects cash to fund operations into Q1 of 2028

Cash, cash equivalents and marketable securities were $621.2 million as of June 30, 2025, compared to $681.4 million...

2M ago

APGE

Analysts Spot 3 Strong Buy Russell 2000 Stocks with 100% Upside

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have...

2M ago

APGE

BEAM

Apogee Therapeutics price target raised to $115 from $100 at BTIG

BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $115 from $100 and keeps a Buy...

3M ago

APGE

3 Best Stocks to Buy Now, 7/9/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3M ago

LLY

APGE

Promising Phase II Results for Apogee Therapeutics’ APG777 Drive Buy Rating and $89 Price Target

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, retaining the price target of...

3M ago

APGE

Promising Potential of Apogee Therapeutics’ APG777 in Atopic Dermatitis Market Drives Buy Rating and Increased Price Target

BTIG analyst Julian Harrison has maintained their bullish stance on APGE stock, giving a Buy rating yesterday. Julian...

3M ago

APGE

APGE FAQ

What was Apogee Therapeutics’s price range in the past 12 months?

Apogee Therapeutics lowest stock price was $26.20 and its highest was $63.50 in the past 12 months.

What is Apogee Therapeutics’s market cap?

Apogee Therapeutics’s market cap is $2.26B.

When is Apogee Therapeutics’s upcoming earnings report date?

Apogee Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 53 days.

How were Apogee Therapeutics’s earnings last quarter?

Apogee Therapeutics released its earnings results on Aug 11, 2025. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$1.094 by -$0.036.

Is Apogee Therapeutics overvalued?

According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Apogee Therapeutics pay dividends?

Apogee Therapeutics does not currently pay dividends.

What is Apogee Therapeutics’s EPS estimate?

Apogee Therapeutics’s EPS estimate is -1.19.

How many shares outstanding does Apogee Therapeutics have?

Apogee Therapeutics has 46,109,768 shares outstanding.

What happened to Apogee Therapeutics’s price movement after its last earnings report?

Apogee Therapeutics reported an EPS of -$1.13 in its last earnings report, missing expectations of -$1.094. Following the earnings report the stock price went down -2.091%.

Which hedge fund is a major shareholder of Apogee Therapeutics?

Currently, no hedge funds are holding shares in APGE

Apogee Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.12%

Trailing 12-Months

Asset Growth

-17.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics (APGE) Earnings & Revenues

Historic Earnings Reports

APGE Stock 12 Month Forecast

Average Price Target

$93.67

▲(143.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","117":"$117","51.75":"$51.8","73.5":"$73.5","95.25":"$95.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$116.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,51.75,73.5,95.25,117],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.86,43.87076923076923,49.88153846153846,55.892307692307696,61.903076923076924,67.91384615384615,73.92461538461538,79.93538461538462,85.94615384615385,91.95692307692308,97.96769230769232,103.97846153846154,109.98923076923077,{"y":116,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.86,42.153076923076924,46.44615384615385,50.73923076923077,55.0323076923077,59.32538461538462,63.61846153846154,67.91153846153847,72.20461538461538,76.49769230769232,80.79076923076923,85.08384615384617,89.37692307692308,{"y":93.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.86,39.56307692307692,41.26615384615385,42.96923076923077,44.67230769230769,46.37538461538462,48.07846153846154,49.78153846153846,51.48461538461538,53.18769230769231,54.89076923076923,56.59384615384616,58.29692307692308,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >